Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

Add NVCN Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/12/2022 4:36:56 PM - Followers: 194 - Board type: Free - Posts Today: 0

Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 

Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.

Latest Earnings Report - March 28th, 2018
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.  https://www.massdevice.com/neovasc-shares-surge-45-affirmed-tiara-patent-case-decision-edwards/

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of SeekingAlpha.com)
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  

MARCH 30, 2018 Article:

Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 
SOURCE:  http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,579,964.PN.&OS=PN/8,579,964&RS=PN/8,579,964

Neovasc's Tiara and other TMVR devices
US$75 MILLION AGREEMENT 12/02/16}}}}

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock


Fred Colen - President and CEO

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 

Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ 


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 




                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"


Concensus Recommendation courtesy of NASDAQ.com 
Updated: April 1st, 2018:   STRONG BUY.
Source: https://www.nasdaq.com/symbol/nvcn/analyst-research

STRONG BUY                                  
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Neovasc to Participate in H.C. Wainwright Global Investment Conference 05/23/2022 12:05:00 PM
NVCN News: Neovasc to Participate in H.C. Wainwright Global Investment Conference 05/23/2022 12:05:00 PM
NVCN News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 05/16/2022 05:06:42 AM
NVCN News: Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule 05/16/2022 05:05:00 AM
NVCN News: Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule 05/16/2022 05:05:00 AM
#11956   Company has 47 million in cash 2.8 million zeusgodmd 05/12/22 04:36:56 PM
#11955   Company’s going to to be sold to highest zeusgodmd 05/10/22 08:48:05 PM
#11954   Thanks for a few shares this am zeusgodmd 04/29/22 11:52:01 AM
#11953   Maybe fund managers can buy now above 5 zeusgodmd 04/29/22 07:50:13 AM
#11952   Only 2 million shares on the common is zeusgodmd 04/28/22 08:56:02 AM
#11951   Nibble nibble zeusgodmd 04/22/22 02:52:59 PM
#11950   When they do a reverse split someone will zeusgodmd 04/20/22 01:25:18 PM
#11949   OK now I know. Thank you. As soon Crapola2theleft 03/18/22 07:21:38 AM
#11948   When you have cms center for Medicare services zeusgodmd 03/17/22 06:04:48 PM
#11947   I'm sorry zeusgodmd, what is a cms reimbursement code? Crapola2theleft 03/17/22 05:35:55 PM
#11946   They have a cms reimbursement code we are zeusgodmd 03/17/22 02:41:07 PM
#11945   It's all up to the idiots at the Crapola2theleft 03/04/22 12:44:10 PM
#11944   Crazy stock needs reducer approval then off to zeusgodmd 03/03/22 05:10:10 PM
#11943   Matter of time USA catches up to Germany zeusgodmd 02/08/22 02:24:21 PM
#11942   Looking good today. Time to double down zeusgodmd 02/08/22 01:22:36 PM
#11941   Thank you! Been with $NVCN for a rrao11 01/07/22 09:21:23 AM
#11940   rrao11, just above the postings yesterday was Cosira-11 Crapola2theleft 01/06/22 10:18:30 AM
#11939   Sorry - I thought there was more good rrao11 01/06/22 09:29:32 AM
#11938   What good news? Please elaborate! TIA rrao11 01/06/22 09:17:02 AM
#11937   At 4:20 this morning GOOD NEWS came in. Crapola2theleft 01/05/22 01:09:41 PM
#11936   FDA, needs to stop doing the white house Crapola2theleft 12/31/21 10:50:05 AM
#11935   Crazy crazy crazy zeusgodmd 12/28/21 04:09:01 PM
#11934   They invested 60 million in this company 5 zeusgodmd 12/27/21 08:56:27 AM
#11933   Stays down here will get bought out cheap. zeusgodmd 12/27/21 08:55:11 AM
#11932   P U a bunch of NVCN. Placed another Crapola2theleft 12/15/21 10:40:20 AM
#11931   If it where Boston scientific or Edward would zeusgodmd 12/13/21 04:41:17 PM
#11930   Remember how the FDA told Fred too make Crapola2theleft 12/13/21 11:27:45 AM
#11929   I like your response time. However, your wrong, Crapola2theleft 12/13/21 11:06:23 AM
#11928   Think stock should be at a minimum 4$ zeusgodmd 12/13/21 10:51:03 AM
#11927   zeusgodmd, your last post was on 10/22/21. Wondering Crapola2theleft 12/13/21 10:47:13 AM
#11925   Maybe some news after hours coming zeusgodmd 10/22/21 03:40:49 PM
#11924   Looking strong today something must be getting ready zeusgodmd 07/12/21 07:59:18 PM
#11923   That was a great run zeusgodmd 06/10/21 08:30:35 PM
#11922   halted hmmm saj 06/10/21 03:13:10 PM
#11921   I don’t know what from maybe one of zeusgodmd 06/02/21 09:12:42 PM
#11920   NVCN nice lil pop in pre saj 06/02/21 09:13:58 AM
#11919   This company can not catch a break. zeusgodmd 05/21/21 12:56:50 PM
#11918   Let’s see if they stay on there script zeusgodmd 05/05/21 07:36:18 AM
#11917   With material news this can spike up several saj 04/30/21 03:40:39 PM
#11916   Someone putting in 9797 is code they need zeusgodmd 04/30/21 11:18:23 AM
#11915   Looks locked up let’s go zeusgodmd 04/21/21 12:30:07 PM
#11914   Looks like 2 pm margin calls will go zeusgodmd 04/20/21 02:23:48 PM
#11913   Last of the cheaps today zeusgodmd 04/20/21 09:58:27 AM
#11912   Hopefully getting enough of these studies done to zeusgodmd 04/20/21 08:07:16 AM
#11911   Trademark will get done maybe with change over zeusgodmd 04/17/21 03:35:30 PM
#11910   Great opportunity with a non event company has zeusgodmd 04/17/21 11:15:01 AM
#11909   Picked up 300k today thanks again zeusgodmd 04/16/21 12:36:47 PM
#11908   Should have been 10$ today. Will have zeusgodmd 04/16/21 12:29:10 PM
#11907   Lowest I’ve seen in awhile could be f’ed zeusgodmd 04/12/21 09:03:56 PM
#11906   Computerized buying down here someone that wants to zeusgodmd 04/09/21 12:50:54 PM
Consent Preferences